Company: MDCXW
Filing Date: 2025-03-07
Form Type: 253G1
Source: 0001062993-25-004966
Chunk: 200

Company: Medicus Pharma Ltd.
Filing Date: 2025-03-07
Form: 253G1
Chunk 200
---
              |   |
| Subsequent events                          |    13 |     |               |   |     |              |   |

Approved on behalf of the Board:

| "Signed"                     |     | "Signed"                 |
| Director - Robert Ciaruffoli |     | Director - Frank Lavelle |

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

<div align='center'>F-3

Medicus Pharma Ltd.

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(unaudited) (expressed in United States dollars, except number of shares)</div>

|                                                                          |       |     |       2024 |   |     | For the three months 
  ended September 30, 
                 2023 |   |     |       2024 |   |     | For the nine months 
 ended September 30, 
                2023 |   |
|:-------------------------------------------------------------------------|------:|:----|-----------:|:--|:----|---------------------:|:--|:----|-----------:|:--|:----|--------------------:|:--|
|                                                                          | Notes |     |          $ |   |     |                    $ |   |     |          $ |   |     |                   $ |   |
| Operating expenses                                                       |       |     |            |   |     |                      |   |     |            |   |     |                     |   |
| General and administrative                                               |     8 |     |  2,201,911 |   |     |              186,418 |   |     |  6,008,493 |   |     |             725,957 |   |
| Research and development                                                 |       |     |    777,514 |   |     |               40,395 |   |     |  2,162,680 |   |     |             159,083 |   |
| Depreciation                                                             |     3 |     |     26,322 |   |     |                    - |   |     |     78,395 |   |     |                   - |   |
| Share-based compensation                                                 |     6 |     |          - |   |     |                    - |   |     |    580,629 |   |     |                   - |   |
| Total operating expenses                                                 |       |     |  3,005,747 |   |     |              226